Abstract
The bacterial type II fatty acid biosynthesis (FASII) pathway is an essential but unexploited target for drug discovery. In this review we summarize SAR studies on inhibitors of InhA, the enoyl-ACP reductase from the FASII pathway in M. tuberculosis. Inhibitor scaffolds that are described include the diaryl ethers, pyrrolidine carboxamides, piperazine indoleformamides, pyrazoles, arylamides, fatty acids and imidazopiperidines, all of which form ternary complexes with InhA and the NAD cofactor, as well as isoniazid and the diazaborines which covalently modify the cofactor. Analysis of the structural data has enabled the development of a common binding mode for the ternary complex inhibitors, which includes a hydrogen bond network, a large hydrophobic pocket and a third ‘size-limited’ binding area comprised of both polar and non-polar groups. A critical factor in InhA inhibition involves ordering of the substrate binding loop, located close to the active site, and a direct link is proposed between loop ordering and slow onset enzyme inhibition. Slow onset inhibitors have long residence times on the enzyme target, a property that is of critical importance for in vivo activity.
Keywords: Fabl, lnhA, enoyl-ACP reductase, drug development, drug-resistant tuberculosis, SAR studies, FASII pathway, Slow onset inhibitors, mycobacterial cell, macrophages, hydrogen bond, large hydrophobic pocket, clinical strains, mammalian cells
Current Topics in Medicinal Chemistry
Title:Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds
Volume: 12 Issue: 7
Author(s): Pan Pan and Peter J. Tonge
Affiliation:
Keywords: Fabl, lnhA, enoyl-ACP reductase, drug development, drug-resistant tuberculosis, SAR studies, FASII pathway, Slow onset inhibitors, mycobacterial cell, macrophages, hydrogen bond, large hydrophobic pocket, clinical strains, mammalian cells
Abstract: The bacterial type II fatty acid biosynthesis (FASII) pathway is an essential but unexploited target for drug discovery. In this review we summarize SAR studies on inhibitors of InhA, the enoyl-ACP reductase from the FASII pathway in M. tuberculosis. Inhibitor scaffolds that are described include the diaryl ethers, pyrrolidine carboxamides, piperazine indoleformamides, pyrazoles, arylamides, fatty acids and imidazopiperidines, all of which form ternary complexes with InhA and the NAD cofactor, as well as isoniazid and the diazaborines which covalently modify the cofactor. Analysis of the structural data has enabled the development of a common binding mode for the ternary complex inhibitors, which includes a hydrogen bond network, a large hydrophobic pocket and a third ‘size-limited’ binding area comprised of both polar and non-polar groups. A critical factor in InhA inhibition involves ordering of the substrate binding loop, located close to the active site, and a direct link is proposed between loop ordering and slow onset enzyme inhibition. Slow onset inhibitors have long residence times on the enzyme target, a property that is of critical importance for in vivo activity.
Export Options
About this article
Cite this article as:
Pan Pan and J. Tonge Peter, Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds, Current Topics in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/156802612799984535
DOI https://dx.doi.org/10.2174/156802612799984535 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Nosocomial Infections: An Increasing Challenge to Medicinal Chemistry)
Current Topics in Medicinal Chemistry Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research
Current Medicinal Chemistry Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa– Implications for Herb- Drug Interactions
Drug Metabolism Letters Significance of Microwave Irradiation in Synthesis of Thiazolidin-4-one Bearing Pyrimidine Analogues: Their <i>in vitro</i> Antimicrobial, Antituberculosis and Antimalarial Studies
Current Microwave Chemistry Antistaphylococcal Activity of Novel Salicylanilide Derivatives
Current Drug Discovery Technologies Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Vertebral Lesions from AIDS-Related Kaposi's Sarcoma
Current HIV Research Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem
Infectious Disorders - Drug Targets Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice
Current Molecular Medicine Synthesis of Cinnamide Dimers as Potential Antibacterial and Antifungal Agents
Letters in Drug Design & Discovery A Rational Approach to Identify Inhibitors of Mycobacterium tuberculosis Enoyl Acyl Carrier Protein Reductase
Current Pharmaceutical Design Principles and Practices of Pathway Modelling
Current Bioinformatics Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents on Oral Vaccine Design
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cyclodextrin Inclusion Complexes Loaded in Particles as Drug Carrier Systems
Current Topics in Medicinal Chemistry Recent Achievements in Understanding Immune Recovery of Children Treated with HAART
Current Pediatric Reviews Tolerance Induction by Gene Transfer to Lymphocytes
Current Gene Therapy Nanomedicine Against Malaria
Current Medicinal Chemistry